Echo IQ Raises A$110m via Institutional Placement

• Firm commitments received for ~A$110m at A$1.45 per share
• Funds to support US commercial expansion and AI product development
• Placement follows FDA clearance and strategic partnerships

Echo IQ Limited (ASX: EIQ) has secured firm commitments for approximately A$110 million in a new institutional placement. The funds will be used to support the company's US commercial expansion strategy and accelerate the development of its AI product portfolio. The placement was priced at A$1.45 per share, representing an 8.8% discount to the last traded price on ASX. The new shares are expected to commence trading on July 7, 2026. The placement follows a period of strategic execution, including FDA clearance for EchoSolv Aortic Stenosis and pending clearance for EchoSolv Heart Failure, as well as commercial partnerships with Pro Medicus and Mayo Clinic.

None

Echo IQ expects to accelerate deployment of EchoSolv across the US and expand its commercial organization.